Departures from the FDA: Six Former Officials Explain Their Reasons for Leaving

Introduction: A Year After the DOGE Service Cuts

It has been roughly one year since the U.S. DOGE Service cuts sent shockwaves through the federal government, prompting significant turnover at key agencies. Among those most affected was the Food and Drug Administration (FDA), where a number of experienced leaders chose to step down during the second Trump administration. To understand the motivations behind these departures, STAT reporter Lizzy Lawrence conducted a series of interviews with six former FDA officials. In a special road-trip edition of STATus Report, Lawrence and a colleague traveled through the leafy suburbs of Washington, D.C., to collect first-person accounts that shed light on the agency’s internal dynamics and the personal decisions that led these professionals to leave.

Why Seasoned Leaders Walked Away

The six officials interviewed represent a cross-section of expertise, including drug evaluation, biologics regulation, and pandemic response. Among them are Richard Pazdur, former director of the FDA’s Center for Drug Evaluation and Research; Sheryl Lard-Whiteford, a longtime leader in the biologics center; and Julie Tierney, a key contributor to Operation Warp Speed. Each had dedicated years—sometimes decades—to public health, yet all eventually chose to resign. Their reasons vary, but common themes emerged: frustration with political interference, erosion of scientific independence, and a changing workplace culture that no longer aligned with their values.

Richard Pazdur: The Fight for Drug Review Independence

Richard Pazdur spent more than two decades at the FDA, overseeing the approval of thousands of cancer drugs. He was known for pushing innovative therapies while maintaining rigorous standards. In his interview, Pazdur revealed that his decision to leave stemmed from increasing pressure to fast-track approvals without adequate evidence, as well as a shift in leadership that marginalized career scientists. He noted that the agency’s credibility—built on decades of impartial reviews—was being undermined by political appointees who prioritized speed over safety. For Pazdur, staying would have meant compromising the very principles he had championed.

Sheryl Lard-Whiteford: A Biologics Veteran’s Turning Point

Sheryl Lard-Whiteford had worked at the FDA’s Center for Biologics Evaluation and Research since the 1990s, helping regulate vaccines, blood products, and gene therapies. She described a gradual erosion of morale that accelerated after the DOGE service cuts. Budget constraints led to hiring freezes and increased workloads, while senior scientists were replaced with outsiders less familiar with the agency’s mission. Lard-Whiteford felt she could no longer guarantee the quality of her team’s work. Her departure, she said, was not a protest but a reluctant admission that the FDA she loved no longer existed.

Julie Tierney: Operation Warp Speed’s Unfinished Legacy

Julie Tierney was part of the historic Operation Warp Speed team that accelerated COVID-19 vaccine development. Her role involved cross-agency coordination, and she saw firsthand how effective collaboration could save lives. However, as the pandemic waned and political priorities shifted, Tierney watched the agency lose focus on preparedness. She cited micromanagement from the White House and a lack of strategic vision as factors that made her role untenable. Tierney left to work on global health initiatives, hoping to preserve the lessons learned from the pandemic response.

Common Threads: Loss of Autonomy and Mission Drift

While each official’s story is unique, several patterns recur across all six accounts. A primary concern was the erosion of the FDA’s independence—a cornerstone of its reputation. Many described being overruled by political staff who lacked scientific backgrounds. Another frequent complaint was mission drift: the agency’s focus shifted from protecting public health to serving political or industry interests. The DOGE service cuts, which reduced administrative support and eliminated certain oversight positions, exacerbated these problems. Several officials mentioned that they no longer felt their expertise was valued, leading to a sense of futility that made staying impossible.

The Impact on FDA Operations and Public Trust

The departure of such seasoned leaders has consequences beyond the individuals involved. The FDA now faces a brain drain, losing institutional knowledge that cannot be easily replaced. New hires often require years to develop the regulatory judgment needed for complex decisions. Additionally, public trust may suffer if the agency is perceived as politicized. The former officials warned that without a commitment to science-based decision-making, the FDA could struggle to maintain its global leadership in drug and device regulation. They urged incoming leaders to rebuild a culture of transparency and respect for career staff.

Conclusion: Lessons for the Future

The testimonies of these six former officials offer a sobering look at what happens when a revered institution faces political pressure and resource constraints. Their stories underscore the importance of protecting the FDA’s scientific mission—not just for the sake of the agency, but for the millions of Americans who rely on its judgments. As the Biden administration and future administrations consider reforms, listening to these voices could help prevent further departures and restore the agency’s morale. For now, the road trip that captured these narratives serves as a powerful reminder that behind every regulatory decision are dedicated public servants whose commitment to health should never be taken for granted.